Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G. Bartelink IH, et al. Among authors: gebhart g. Clin Pharmacol Ther. 2019 Jul;106(1):148-163. doi: 10.1002/cpt.1211. Epub 2018 Oct 6. Clin Pharmacol Ther. 2019. PMID: 30107040 Free PMC article. Review.
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P. Gebhart G, et al. Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598545 Free article. Clinical Trial.
N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.
Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G. Wimana Z, et al. Among authors: gebhart g. Oncotarget. 2017 Apr 10;8(34):56185-56198. doi: 10.18632/oncotarget.17015. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915583 Free PMC article.
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).
Mileva M, de Vries EGE, Guiot T, Wimana Z, Deleu AL, Schröder CP, Lefebvre Y, Paesmans M, Stroobants S, Huizing M, Aftimos P, Tol J, Van der Graaf WTA, Oyen WJG, Vugts DJ, Menke-van der Houven van Oordt CW, Brouwers AH, Piccart-Gebhart M, Flamen P, Gebhart G. Mileva M, et al. Among authors: gebhart g. NPJ Breast Cancer. 2024 Jan 6;10(1):4. doi: 10.1038/s41523-023-00610-6. NPJ Breast Cancer. 2024. PMID: 38184611 Free PMC article.
Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial.
Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, Guiot T, de Vries EGE, Schröder CP, Menke-van der Houven van Oordt CW, Maetens M, Majjaj S, Larsimont D, Rothé F, Sotiriou C, Gebhart G. Rediti M, et al. Among authors: gebhart g. Clin Cancer Res. 2025 Jan 6;31(1):110-121. doi: 10.1158/1078-0432.CCR-24-1007. Clin Cancer Res. 2025. PMID: 39470686
390 results